David Ricks, Eli Lilly CEO (Carolyn Kaster/AP Images)

Lil­ly inks $2.4B cash deal to buy DICE and its im­munol­o­gy pipeline

Eli Lil­ly is join­ing the “blis­ter­ing” pace of M&A this year as it bets $2.4 bil­lion in cash on DICE Ther­a­peu­tics, a pub­licly trad­ed biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.